21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Forcefield_NCAA: Ab Initio Charge Parameters to Aid in the Discovery and Design of Therapeutic Proteins and Peptides with Unnatural Amino Acids and Their Application to Complement Inhibitors of the Compstatin Family

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We describe the development and testing of ab initio derived, AMBER ff03 compatible charge parameters for a large library of 147 noncanonical amino acids including β- and N-methylated amino acids for use in applications such as protein structure prediction and de novo protein design. The charge parameter derivation was performed using the RESP fitting approach. Studies were performed assessing the suitability of the derived charge parameters in discriminating the activity/inactivity between 63 analogs of the complement inhibitor Compstatin on the basis of previously published experimental IC 50 data and a screening procedure involving short simulations and binding free energy calculations. We found that both the approximate binding affinity ( K*) and the binding free energy calculated through MM-GBSA are capable of discriminating between active and inactive Compstatin analogs, with MM-GBSA performing significantly better. Key interactions between the most potent Compstatin analog that contains a noncanonical amino acid are presented and compared to the most potent analog containing only natural amino acids and native Compstatin. We make the derived parameters and an associated web interface that is capable of performing modifications on proteins using Forcefield_NCAA and outputting AMBER-ready topology and parameter files freely available for academic use at http://selene.princeton.edu/FFNCAA. The forcefield allows one to incorporate these customized amino acids into design applications with control over size, van der Waals, and electrostatic interactions.

          Related collections

          Most cited references46

          • Record: found
          • Abstract: found
          • Article: not found

          ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules.

          We have recently completed a full re-architecturing of the ROSETTA molecular modeling program, generalizing and expanding its existing functionality. The new architecture enables the rapid prototyping of novel protocols by providing easy-to-use interfaces to powerful tools for molecular modeling. The source code of this rearchitecturing has been released as ROSETTA3 and is freely available for academic use. At the time of its release, it contained 470,000 lines of code. Counting currently unpublished protocols at the time of this writing, the source includes 1,285,000 lines. Its rapid growth is a testament to its ease of use. This chapter describes the requirements for our new architecture, justifies the design decisions, sketches out central classes, and highlights a few of the common tasks that the new software can perform. © 2011 Elsevier Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The future of peptide-based drugs.

            The suite of currently used drugs can be divided into two categories - traditional 'small molecule' drugs with typical molecular weights of 5000 Da that are not orally bioavailable and need to be delivered via injection. Due to their small size, conventional small molecule drugs may suffer from reduced target selectivity that often ultimately manifests in human side-effects, whereas protein therapeutics tend to be exquisitely specific for their targets due to many more interactions with them, but this comes at a cost of low bioavailability, poor membrane permeability, and metabolic instability. The time has now come to reinvestigate new drug leads that fit between these two molecular weight extremes, with the goal of combining advantages of small molecules (cost, conformational restriction, membrane permeability, metabolic stability, oral bioavailability) with those of proteins (natural components, target specificity, high potency). This article uses selected examples of peptides to highlight the importance of peptide drugs, some potential new opportunities for their exploitation, and some difficult challenges ahead in this field. © 2012 John Wiley & Sons A/S.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Areas, volumes, packing and protein structure.

              F Richards (1977)
                Bookmark

                Author and article information

                Journal
                ACS Synth Biol
                ACS Synth Biol
                sb
                asbcd6
                ACS Synthetic Biology
                American Chemical Society
                2161-5063
                2161-5063
                06 January 2015
                06 January 2014
                19 December 2014
                : 3
                : 12
                : 855-869
                Affiliations
                [1]Department of Chemical and Biological Engineering, Princeton University , Princeton, New Jersey 08544, United States
                Author notes
                [* ]Phone: 609-258-4595. Fax: 609-258-0211. E-mail: floudas@ 123456titan.princeton.edu .
                Article
                10.1021/sb400168u
                4277759
                24932669
                e05853d7-57e7-45c1-bda8-e0dfb55a562f
                Copyright © 2014 American Chemical Society

                This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

                History
                : 21 October 2013
                Funding
                National Institutes of Health, United States
                Categories
                Research Article
                Custom metadata
                sb400168u
                sb-2013-00168u

                Molecular biology
                noncanonical amino acids,unnatural amino acids,amber partial charges,complement,inhibitors,compstatin,molecular dynamics

                Comments

                Comment on this article